Scientific Publications

Trilaciclib

date publication
Sep 2019 Trilaciclib decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab
ESMO 2019 Congress Poster: Daniel et al., Abstract #1742PD (pdf) or SmartPoster (mobile optimized) 
Sep 2019 Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Tan et al., Lancet Oncology 
Sep 2019 Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GCb) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized, open-label, Phase 2 trial
ESMO 2019 Congress Presentation: O’Shaugnessy et al., Oral Presentation (pdf) 
Aug 2019 Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial
Weiss et al., Annals of Oncology 
Jun 2019 Positive effects of trilaciclib on patient myelosuppression-related symptoms and functioning: results from three phase 2 randomized, double-blind, placebo-controlled small cell lung cancer trials
MASCC Oral Presentation: Weiss et al., Abstract #MASCC9-0845 (pdf)
Jun 2019 Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer
ASCO Oral Presentation: Hart et al., Abstract #8505 (pdf)
Dec 2018 Trilaciclib, a CDK4/6 inhibitor, dosed with Gemcitabine, Carboplatin in metastatic triple negative breast cancer (mTNBC) patients: Preliminary Phase 2 results
SABCS Poster: O'Shaughnessy et al., Abstract #1191 (pdf)
Nov 2018 Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models
EORTC-NCI-AACR Symposium Poster: Sorrentino et al., Abstract #377 (pdf)
Oct 2018 Trilaciclib decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy
ESMO 2018 Congress Poster: Dragnev et al., Abstract #1666PD (pdf)
Oct 2018 Trilaciclib preserves and enhances immune system function in extensive-stage small cell lung cancer (SCLC) patients receiving first-line chemotherapy
ESMO 2018 Congress Poster: Sorrentino et al., Abstract #1671P (pdf)
Apr 2018 Transient exposure to trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates and promotes a pro-inflammatory tumor microenvironment
AACR Annual Meeting Poster: Lai et al., Abstract #1752 (pdf)
Nov 2017 CDK4/6 inhibition augments anti-tumor immunity by enhancing T cell activation
Deng et al., Cancer Discovery
Jun 2017 Trilaciclib (G1T28): a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC): Phase 1b results
ASCO Annual Meeting Poster: Rocha Lima et al., Abstract #8568 (pdf)
Apr 2017 Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He et al., Science Translational Medicine
Apr 2017 Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models
AACR Annual Meeting Poster: Sorrentino et al., Abstract #5628 (pdf)
Dec 2016 Trilaciclib (G1T28), a cyclin dependent kinase 4/6 inhibitor, in combination with topotecan for previously treated small cell lung cancer: preliminary results
WCLC Annual Meeting Poster: Hart et al., Abstract #5213 (pdf)
Nov 2016 Trilaciclib (G1T28), a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy
EORTC-NCI-AACR Symposium Poster: Roberts et al., Abstract #439 (pdf)
May 2016 Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression
Bisi et al., Molecular Cancer Therapeutics (pdf)
Apr 2016 G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results
AACR Annual Meeting Poster: Rocha Lima et al., Abstract #CT151 (pdf)
May 2015 Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression
ASCO Annual Meeting Poster: Roberts et al., Abstract #2529 (pdf)
May 2015 First-in-human phase 1a safety, PK, and PD study of the CDK4/6 inhibitor G1T28 (G1T28-1-01)
ASCO Annual Meeting Poster: Tiessen et al., Abstract #2527 (pdf)
Apr 2015 Pre-clinical characterization of G1T28, a novel CDK4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies
AACR Annual Meeting Poster: Bisi et al., Abstract #1784 (pdf)

Lerociclib

Date Publication
Sep 2019 Lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed continuously in combination with osimertinib for EGFRmut non-small cell lung cancer: Initial Phase 1b results
ESMO 2019 Congress Poster: Berz et al., Abstract #1537P (pdf) or SmartPoster (mobile optimized)
Apr 2019 CDK4/6 inhibition with lerociclib (G1T38) delays acquired resistance to targeted therapies in preclinical models of non-small cell lung cancer
AACR Annual Meeting Poster: Freed et al., Abstract #4415 (pdf)
Apr 2019 CDK4/6 inhibition with lerociclib enhances response to PI3K or ERK inhibitors in high-throughput, ex vivo pancreatic PDX screens
AACR Annual Meeting Poster: Dai et al., Abstract #4732 (pdf)
Jun 2018 G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: preliminary phase 1b results
ASCO Annual Meeting Poster: Bulat et al., Abstract #1061 (pdf)
Apr 2018 The CDK4/6 inhibitor, G1T38, enhances response to targeted therapies in preclinical models of non-small cell lung cancer
AACR Annual Meeting Poster: Sorrentino et al., Abstract #1522 (pdf)
Apr 2017 CDK4/6 therapeutic intervention and viable alternative to taxanes in CRPC
Stice et al., Molecular Cancer Research (pdf)
Feb 2017 Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors
Bisi et al., Oncotarget (pdf)
Apr 2016 G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of RB competent tumors
AACR Annual Meeting Poster: Sorrentino et al., Abstract #2824 (pdf)
Apr 2016 Effects of a CDK 4/6 inhibitor, G1T38, in androgen receptor sensitive and resistant models of castrate resistant prostate cancer
AACR Annual Meeting Poster: Stice et al., Abstract #2820 (pdf)

G1T48

Date Publication
Sep 2019

First-in-human dose-escalation study of G1T48, an oral selective estrogen receptor degrader (SERD), in postmenopausal women with ER+/HER2- locally advanced or metastatic breast cancer (ABC)
ESMO 2019 Congress Poster: Dees et al., Abstract #340P (pdf) or SmartPoster (mobile optimized)

Apr 2017

Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in an animal model of tamoxifen resistant breast cancer
AACR Annual Meeting Poster: Wardell et al., Abstract #5641 (pdf)

Preclinical Programs

Date Publication
Apr 2019

Development of CDK2 inhibitors to overcome primary and acquired resistance to CDK4/6 inhibition
AACR Annual Meeting Poster: Hall et al., Abstract #4414 (pdf)

Apr 2019 Novel CDK9 inhibitors to treat CDK4/6 resistant tumors
AACR Annual Meeting Poster: Brighton et al., Abstract #4426 (pdf)